Jeffrey Scott Sherman - Feb 21, 2025 Form 4 Insider Report for NEOGENOMICS INC (NEO)

Signature
/s/ Ali Olivo, Attorney-in-Fact
Stock symbol
NEO
Transactions as of
Feb 21, 2025
Transactions value $
$0
Form type
4
Date filed
2/25/2025, 04:38 PM
Previous filing
Jan 16, 2025
Next filing
May 6, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NEO Common Stock Options Exercise $0 +15.5K +12.36% $0.00 141K Feb 23, 2025 Direct F1, F2
transaction NEO Common Stock Tax liability $0 -4.21K -2.98% $0.00 137K Feb 23, 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NEO Stock Option (Right to Buy) Award $0 +215K $0.00 215K Feb 21, 2025 Common Stock 215K $13.05 Direct F4, F5
transaction NEO Restricted Stock Unit Award $0 +126K $0.00 126K Feb 21, 2025 Common Stock 126K $0.00 Direct F6, F7
transaction NEO Restricted Stock Unit Options Exercise $0 -15.5K -33.33% $0.00 31.1K Feb 23, 2025 Common Stock 15.5K $0.00 Direct F7, F8
holding NEO Stock Option (Right to Buy) 249K Feb 21, 2025 Common Stock 249K $11.62 Direct F9
holding NEO Stock Option (Right to Buy) 73K Feb 21, 2025 Common Stock 73K $19.65 Direct F10
holding NEO Restricted Stock Unit 26K Feb 21, 2025 Common Stock 26K $0.00 Direct F7, F11
holding NEO Performance Stock Unit 39K Feb 21, 2025 Common Stock 39K $0.00 Direct F7, F12
holding NEO Stock Option (Right to Buy) 77.9K Feb 21, 2025 Common Stock 77.9K $16.45 Direct F13
holding NEO Performance Stock Unit 46.6K Feb 21, 2025 Common Stock 46.6K $0.00 Direct F7, F14
holding NEO Restricted Stock Unit 59.4K Feb 21, 2025 Common Stock 59.4K $0.00 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
F2 This balance includes 1,982 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP). The shares were acquired in transactions exempt from Section 16b-3.
F3 Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
F4 This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
F5 On February 21, 2025, Mr. Sherman was granted 214,900 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F6 On February 21, 2025, Mr. Sherman was granted 126,476 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F7 Once vested, the shares of common stock are not subject to expiration.
F8 On February 23, 2024, Mr. Sherman was granted 46,606 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F9 On December 5, 2022, Mr. Sherman was granted 249,169 stock options. These awards vest ratably over four years with the first tranche vesting on December 7, 2023.
F10 On May 11, 2023, Mr. Sherman was granted 73,016 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F11 On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F12 On May 11, 2023, Mr. Sherman was granted 39,016 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to theperformance criteria is58,524. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stockover the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
F13 On February 23, 2024, Mr. Sherman was granted 77,913 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F14 On February 23, 2024, Mr. Sherman was granted 46,606 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuantto the performance criteriais 69,910. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company'scommon stock over the 20-day trailing trading periodat the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based onthe achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company